Pinned Tweet
*Updated* 500M+ Biotech Public Offerings 2024-2026 (6/20/26) added (CYTK) I will create a new one at YE. $XBI
1/ 500M+ biotech offerings 2024-2026 $XBI
ABVX - 743M PO at 64.00 (2025)
INSM - 750M PO at 96.00 (2025)
PCVX - 1.3B PO at 103.00 (2024)
PCVX - 632M PO at 50.00 (51.00)
VKTX - 550M PO at 85.00 (2024)
IONS - 500M PO at 43.50 (2024)
RVMD - 750M PO at 46.00 (2024)
RVMD - 1.65B PO
$KYNB "Subject to the execution of either a strategic partnership or an external capital raise, we plan on initiating the pivotal Phase 3 trial in the first quarter of 2027."
This is a fancy way of saying they will be seeking strategic alternatives in Q1 2027.
2
473
$PASG will be worth revisiting after the merger. sec.gov/Archives/edgar/data/…
385
Due to all the planes being grounded all biotech M&A is paused for now. Sorry guys.
The @FAAnews issued a nationwide ground stop for all U.S. airports following a communication issue impacting all Air Route Traffic Control Centers. FAA technicians are investigating the issue. We will provide immediate updates as we have them.
$LGVN cash is low. Just need them to update their "cash conservation measures" and seee some signs of bottoming then they are good to go for strat alt. As long as they don't dilute the piss out of it to keep the low float it could spike like NXTC did on a merger announcement.
2
4
932
$CNSP would prefer to snag shares at the private placement price at 2.30. Volume is non-existent though.
303
$TCRX cash through end of 2027. Preclin data for in-vivo tumor asset in q1 2027. If they can't raise then will be forced to strat alt. We wait for now.
296
$XBI despite the carnage still maintaining a decent trend on the daily. Should retest the 200MA daily though.
1
2
421














